Mizuho Maintains Buy on ResMed, Lowers Price Target to $160
Portfolio Pulse from Benzinga Newsdesk
Mizuho analyst Anthony Petrone maintains a 'Buy' rating on ResMed (NYSE:RMD) but lowers the price target from $180 to $160.
October 30, 2023 | 7:06 pm
News sentiment analysis
Sort by:
Ascending
NEUTRAL IMPACT
ResMed's price target has been lowered from $180 to $160 by Mizuho, though the 'Buy' rating is maintained.
The news directly pertains to ResMed. While the lowered price target might initially seem negative, the maintained 'Buy' rating indicates that Mizuho still sees potential in the stock. This could lead to neutral short-term price movement.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100